The recent prospectively designed ADAPTeR study demonstrated that the abundance of clonally expanded CD8+ T cells present in the tumor at diagnosis and their persistence during treatment with anti-PD1 therapy were predictors of response (13). This evidence concerns the gene CD8A and neoplasm.